NovaBridge Biosciences News and Activities
Presence
Headquarters: China
NovaBridge Biosciences is a company listed under the stock ticker IMAB (CN).
Acquisition, funding and merger involving NovaBridge Biosciences.
- The new name of I-Mab Biopharma is NovaBridge Biosciences. (posted on October 20 2025).
- I-Mab Biopharma will change its company name to NovaBridge Biosciences. (posted on October 17 2025).
Executives
View the org chart displaying its 20 main executives
Most searched biographies at NovaBridge Biosciences
- Sean Fu, Chief Executive Officer
- Wei Fu, Executive Chairman of the Board
- Robert Lenz, Independent Director
Popular executive movements at NovaBridge Biosciences
- Claire Xu, who was Senior Vice President, Clinical Development, is promoted to Senior Vice President, Research and Development Center of Excellence (posted on April 22 2026).
- Roshni Patel has joined the company as Head of Quality (posted on April 22 2026).
- Mark Hagler has joined the company as President and Chief Commercial Officer (posted on April 22 2026).
Click here to view some more movements at NovaBridge Biosciences
Create your alert
to follow the executive moves at NovaBridge Biosciences.
Pharmaceuticals
NovaBridge Biosciences has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Corden Pharma has announced the acquisition of AmbioPharm (posted on June 5 2026).
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
Popular contacts in Pharmaceuticals
News
Press releases by NovaBridge Biosciences
- NovaBridge Biosciences | NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
- NovaBridge Biosciences | News
- NovaBridge Biosciences | NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
- NovaBridge Biosciences | News
- I-Mab | I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China
- I-Mab | I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
- I-Mab | News Releases
- I-Mab | I-Mab to Host 2022 R&D Day
- I-Mab | I-Mab Receives Top Rankings in Five Categories by Institutional Investor
- I-Mab | I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210
- View more press releases Close
Social media about NovaBridge Biosciences
- NovaBridge Biosciences on Wikipedia, Google News & Yahoo Finance
- NovaBridge Biosciences on LinkedIn, X (Twitter) & YouTube
